Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor

Comorbidities at diagnosis among patients with chronic myeloid leukemia in chronic phase (CML‐CP) may affect their overall survival (OS) rate even in the tyrosine kinase inhibitor (TKI) era. However, the prognostic impact of comorbidities in patients with CML‐CP treated with a second‐generation TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Ono, Takaaki, Takahashi, Naoto, Kizaki, Masahiro, Kawaguchi, Tatsuya, Suzuki, Ritsuro, Yamamoto, Kazuhito, Ohnishi, Kazunori, Naoe, Tomoki, Matsumura, Itaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541002/
https://www.ncbi.nlm.nih.gov/pubmed/33404088
http://dx.doi.org/10.1111/cas.14580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541002/
https://www.ncbi.nlm.nih.gov/pubmed/33404088
http://dx.doi.org/10.1111/cas.14580

Ejemplares similares